Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomised, double-blind, parallel-group, placebo-controlled study
Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomised, double-blind, parallel-group, placebo-controlled study
Effect of F2695 on Functional Recovery After Ischemic Stroke (LIFE)
Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomised, double-blind, parallel-group, placebo-controlled study
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
80
Years old
Gender
All
Therapeutic area :
Cardiovascular
Disease :
Ischemic stroke
Study medication :
F2695
Phase :
Phase II
Start Date :
18 June 2012
End date :
11 February 2015
Study ID :
F02695 LP 205
EudraCT/CTIS number :
2012-001592-37
CT.gov Number :
NCT01639014
Send by email